Meeting
2019 ASCO Annual Meeting
Retrospective study of capecitabine and temozolomide in advanced lung neuroendocrine neoplasms.
Authors
Taymeyah E. Al-Toubah
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Taymeyah E. Al-Toubah , Brian Morse , Jonathan R. Strosberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8542)
DOI
10.1200/JCO.2019.37.15_suppl.8542
Abstract #
8542
Poster Bd #
298
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads
First Author: Taymeyah E. Al-Toubah
Poster
2019 Gastrointestinal Cancers Symposium
Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
First Author: David Chan
Poster
2014 Gastrointestinal Cancers Symposium
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
First Author: Robert Lance Fine